Positive Long-Term Data For BENLYSTA (formerly LYMPHOSTAT-B(R)) In Patients With Active Lupus

Main Category: Lupus
Article Date: 15 Jun 2009 - 5:00 PDT

Current Article Ratings:

Patient / Public:		4.41 (17 votes)
Healthcare Prof:		3 (1 votes)

Human Genome Sciences (HGS) has reported continuation data from a Phase II study of BENLYSTA™ (belimumab, formerly LymphoStat-B®) showing sustained improvement in patients with active systemic lupus after four years of treatment. The data was presented at the EULAR 2009 scientific meeting in Copenhagen, Denmark.

Early results from a 52-week Phase III study of BENLYSTA™ are expected to be announced in July and results from a 76-week study are scheduled to be released in November.

BENLYSTA™ is being co-developed and commercialized by HGS and GlaxoSmithKline (GSK).

The HGS website has the full release about this additional Phase II data.

Source
Lupus Foundation of America

View drug information on Benlysta.

Additional
References
Citations

Article adapted by Medical News Today from original press release.
Visit our lupus section for the latest news on this subject.

There are no references listed for this article.

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Lupus Foundation of America. "Positive Long-Term Data For BENLYSTA (formerly LYMPHOSTAT-B(R)) In Patients With Active Lupus." Medical News Today. MediLexicon, Intl., 15 Jun. 2009. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/153936.php>

APA

Lupus Foundation of America. (2009, June 15). "Positive Long-Term Data For BENLYSTA (formerly LYMPHOSTAT-B(R)) In Patients With Active Lupus." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/153936.php.

Please note: If no author information is provided, the source is cited instead.

Rate this article:
(Hover over the stars then click to rate)

Patient / Public:

Health Professional:

Add Your Opinion

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Lupus

What is Lupus?

Lupus is an autoimmune disease where the body's immune system becomes hyperactive and attacks normal, healthy tissue. This results in symptoms such as inflammation, swelling, and damage to joints, skin, kidneys, blood, the heart, and lungs. Read more...

Follow Our Lupus News On Twitter

Get the latest news for this category delivered straight to your Twitter account. Simply visit our Lupus Twitter account and select the 'follow' option.

Conditions Information

View list of all 'What Is...' articles »

Your Name:*
E-mail Address:*
Title For Opinion:*
Opinion:*

This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*